SPPI - Spectrum Pharmaceuticals - Vol. VI
- Creatore Discussione ermes061958
- Data di inizio
Bravo Pier... io son rimasto dentro ancora con tutto.. anche se in gain altissimo spero e credo che tornerà a salire.. ieri dovrebbero essere state delle prese di beneficio che ci stanno.. credo che già da oggi dovrebbe risalire... vediamo.. buona giornata a tutti..
LOROCIU65
""ONLY THE BRAVE""
- Registrato
- 1/3/06
- Messaggi
- 31.837
- Punti reazioni
- 689
uscito ieri un articolo su seeking alpha di Adam...che dice che non vale 2 billion per i farmaci che ha..ecco innesco della discesa-Buongiorno a tutti... stasera comunicano i dati.. speriamo bene.. per ora l'azione ha tenuto abbastanza bene dai.. era fisiologico un po' di storno.. i target price emessi vanno anche a 32$... vediamo intanto oggi come và...
stasera comunicano i dati.. speriamo bene.. per ora l'azione ha tenuto abbastanza bene dai.. era fisiologico un po' di storno.. i target price emessi vanno anche a 32$... vediamo intanto oggi come và...December 17, 2017
Spectrum Pharmaceuticals Announces Leadership Changes
Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors
Thomas J. Riga Named Chief Operating Officer
Stuart M. Krassner, ScD, PsyD Named Chairman of the Board
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer, and announced leadership changes under which Joseph W. Turgeon, the current President and Chief Operating Officer, has been named President and Chief Executive Officer and elected to the Board of Directors, and current Director Stuart M. Krassner, ScD, PsyD, has been named Chairman of the Board. In addition, Thomas J. Riga, who currently serves as Executive Vice President, Chief Commercial Officer and Head of Business Development, has been named Chief Operating Officer. These changes are effective immediately.
"The Board of Directors thanks Dr. Shrotriya for his contributions to Spectrum over the past fifteen years," said Dr. Krassner, Chairman. "The Board believes that now is the right time to effect these leadership changes. Mr. Turgeon and Mr. Riga have nearly 50 years of combined industry experience and the Board believes that they are the right leaders for Spectrum as the Company enters its next chapter."
"I am honored to serve as Spectrum's next CEO and appreciate the confidence the Board has placed in me to guide the Company forward," said Mr. Turgeon, President and CEO. "We are at an exciting point in Spectrum's history, and I look forward to driving the operation forward as we maintain our focus on our product pipeline."
Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had served as Spectrum's President and Chief Operating Officer since April 2014, and had previously served as the Company's Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales.
Mr. Riga brings over 15 years of pharmaceutical sales and management experience in various positions at Amgen, Eli Lilly and Dendreon, including as Vice President of Sales at Dendreon. He had served as Spectrum's Executive Vice President, Chief Commercial Officer and Head of Business Development since June 2017, and previously served as Spectrum's Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.
Dr. Krassner has served as a director of Spectrum since December 2004, and was previously a member of Spectrum's Scientific Advisory Board from 1996 to 2001. Dr. Krassner's career spans nearly four decades of experience in positions of increasing responsibility at the University of California at Irvine, most recently as Professor of Developmental and Cell Biology at the School of Biological Sciences. Dr. Krassner is Professor Emeritus, University of California, Irvine and has also been retained by pharmaceutical, medical device and other companies, including Allergan Pharmaceuticals, Lasermed Corporation, Automated Microbiology Systems, and In Vitro International, among others, to provide scientific and regulatory advisory services, including FDA compliance. He is a past member of the American Academy for the Advancement of Sciences, and the American Society of Tropical Medicine and Hygiene, among others.
Spectrum Pharmaceuticals Announces Leadership Changes
Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors
Thomas J. Riga Named Chief Operating Officer
Stuart M. Krassner, ScD, PsyD Named Chairman of the Board
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer, and announced leadership changes under which Joseph W. Turgeon, the current President and Chief Operating Officer, has been named President and Chief Executive Officer and elected to the Board of Directors, and current Director Stuart M. Krassner, ScD, PsyD, has been named Chairman of the Board. In addition, Thomas J. Riga, who currently serves as Executive Vice President, Chief Commercial Officer and Head of Business Development, has been named Chief Operating Officer. These changes are effective immediately.
"The Board of Directors thanks Dr. Shrotriya for his contributions to Spectrum over the past fifteen years," said Dr. Krassner, Chairman. "The Board believes that now is the right time to effect these leadership changes. Mr. Turgeon and Mr. Riga have nearly 50 years of combined industry experience and the Board believes that they are the right leaders for Spectrum as the Company enters its next chapter."
"I am honored to serve as Spectrum's next CEO and appreciate the confidence the Board has placed in me to guide the Company forward," said Mr. Turgeon, President and CEO. "We are at an exciting point in Spectrum's history, and I look forward to driving the operation forward as we maintain our focus on our product pipeline."
Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had served as Spectrum's President and Chief Operating Officer since April 2014, and had previously served as the Company's Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales.
Mr. Riga brings over 15 years of pharmaceutical sales and management experience in various positions at Amgen, Eli Lilly and Dendreon, including as Vice President of Sales at Dendreon. He had served as Spectrum's Executive Vice President, Chief Commercial Officer and Head of Business Development since June 2017, and previously served as Spectrum's Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.
Dr. Krassner has served as a director of Spectrum since December 2004, and was previously a member of Spectrum's Scientific Advisory Board from 1996 to 2001. Dr. Krassner's career spans nearly four decades of experience in positions of increasing responsibility at the University of California at Irvine, most recently as Professor of Developmental and Cell Biology at the School of Biological Sciences. Dr. Krassner is Professor Emeritus, University of California, Irvine and has also been retained by pharmaceutical, medical device and other companies, including Allergan Pharmaceuticals, Lasermed Corporation, Automated Microbiology Systems, and In Vitro International, among others, to provide scientific and regulatory advisory services, including FDA compliance. He is a past member of the American Academy for the Advancement of Sciences, and the American Society of Tropical Medicine and Hygiene, among others.
Spectrum Pharmaceuticals, Inc. (SPPI) Stock Price, Quote, History & News - Yahoo Finance
penso domani di entrare con poco.
penso domani di entrare con poco.
Infatti vale 457M$.
L' articolo era di 2 anni fa...
Penso possa si possa valutare, dovrebbe avere qualche catalyst nel 2020
Io mi riferivo alla capitalizzazione attuale. Ora vale 395M$.
Non sono d'accordo. E' sottostimata almeno di 5$. Egro entrato a 3.70$ con poco.
Vi sono anche altri motivi per qui ho fatto questo investimento e continuerò a comprare titoli di questo comparto. La ricerca sul cancro. CAR-T.
Mi spiego meglio.
Merck and Sanofi Are Both Acquiring Cancer-Drug Developers
Nel mese in corso ci sono stati 2 mega-acquisizioni. Una è appunto ARQULE di cui non mi dilungo.
Le mega-aquisizioni vengono in genere fatte a molecole/farmaco approvato.
Nel caso di SPPI la prova è stata negativa. Ma le società acquistate sono state valutate 3-4 volte il loro valore di libro. Il ns. SPPI CAPITALIZZA meno della metà.
Concludo per non annoiare il lettore che anche in Italia abbiamo una signora azienda. Ma questa sezione non è per i titoli italiani.
Mi spiego meglio.
Merck and Sanofi Are Both Acquiring Cancer-Drug Developers
Nel mese in corso ci sono stati 2 mega-acquisizioni. Una è appunto ARQULE di cui non mi dilungo.
Le mega-aquisizioni vengono in genere fatte a molecole/farmaco approvato.
Nel caso di SPPI la prova è stata negativa. Ma le società acquistate sono state valutate 3-4 volte il loro valore di libro. Il ns. SPPI CAPITALIZZA meno della metà.
Concludo per non annoiare il lettore che anche in Italia abbiamo una signora azienda. Ma questa sezione non è per i titoli italiani.
Tanto per capire chi e che cosa sono e che cosa fanno:
Spectrum Pharmaceuticals, Inc. sviluppa e commercializza prodotti oncologici ed ematologici. La società offre KHAPZORY, un nuovo analogo dei folati e il levo-isomero farmacologicamente attivo di d e 1-leucovorin; FOLOTYN, un inibitore metabolico analogo dei folati per il linfoma periferico a cellule T (PTCL); Iniezione di ZEVALIN per il trattamento del linfoma non Hodgkin; MARQIBO per pazienti adulti con leucemia linfoblastica acuta cromosomica Philadelphia; BELEODAQ, un istone deacytelase, o HDAC, inibitore per il trattamento di pazienti con PTCL recidivante o refrattario; ed EVOMELA da utilizzare come trattamento di condizionamento prima del trapianto autologo di cellule staminali in pazienti affetti da mieloma multiplo. Sta inoltre sviluppando POZIOTINIB, un inibitore pan-HER per i tumori del carcinoma polmonare non a piccole cellule; ROLONTIS per neutropenia indotta da chemioterapia; e QAPZOLA per carcinoma vescicale invasivo non muscolare. La società vende i suoi farmaci attraverso organizzazioni di acquisto di gruppo, grossisti e direttamente a ospedali e centri oncologici negli Stati Uniti; e attraverso distributori in Europa. Ha una partnership strategica con Servier Canada, Inc .; accordo di licenza e sviluppo con Cell Therapeutics, Inc .; accordi di licenza con Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc. e Mundipharma International Corporation Limited; accordo di collaborazione per lo sviluppo e la commercializzazione con Allergan, Inc .; accordo di collaborazione con Nippon Kayaku Co., LTD .; accordo di licenza e collaborazione con Onxeo DK; e accordi di co-sviluppo e commercializzazione con Hanmi Pharmaceutical Co. Ltd e MD Anderson Cancer Center dell'Università del Texas. La società era precedentemente nota come NeoTherapeutics, Inc. e ha cambiato il suo nome in Spectrum Pharmaceuticals, Inc. nel dicembre 2002. Spectrum Pharmaceuticals, Inc. è stata fondata nel 1987 e ha sede a Henderson, Nevada.
Spectrum Pharmaceuticals, Inc. sviluppa e commercializza prodotti oncologici ed ematologici. La società offre KHAPZORY, un nuovo analogo dei folati e il levo-isomero farmacologicamente attivo di d e 1-leucovorin; FOLOTYN, un inibitore metabolico analogo dei folati per il linfoma periferico a cellule T (PTCL); Iniezione di ZEVALIN per il trattamento del linfoma non Hodgkin; MARQIBO per pazienti adulti con leucemia linfoblastica acuta cromosomica Philadelphia; BELEODAQ, un istone deacytelase, o HDAC, inibitore per il trattamento di pazienti con PTCL recidivante o refrattario; ed EVOMELA da utilizzare come trattamento di condizionamento prima del trapianto autologo di cellule staminali in pazienti affetti da mieloma multiplo. Sta inoltre sviluppando POZIOTINIB, un inibitore pan-HER per i tumori del carcinoma polmonare non a piccole cellule; ROLONTIS per neutropenia indotta da chemioterapia; e QAPZOLA per carcinoma vescicale invasivo non muscolare. La società vende i suoi farmaci attraverso organizzazioni di acquisto di gruppo, grossisti e direttamente a ospedali e centri oncologici negli Stati Uniti; e attraverso distributori in Europa. Ha una partnership strategica con Servier Canada, Inc .; accordo di licenza e sviluppo con Cell Therapeutics, Inc .; accordi di licenza con Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc. e Mundipharma International Corporation Limited; accordo di collaborazione per lo sviluppo e la commercializzazione con Allergan, Inc .; accordo di collaborazione con Nippon Kayaku Co., LTD .; accordo di licenza e collaborazione con Onxeo DK; e accordi di co-sviluppo e commercializzazione con Hanmi Pharmaceutical Co. Ltd e MD Anderson Cancer Center dell'Università del Texas. La società era precedentemente nota come NeoTherapeutics, Inc. e ha cambiato il suo nome in Spectrum Pharmaceuticals, Inc. nel dicembre 2002. Spectrum Pharmaceuticals, Inc. è stata fondata nel 1987 e ha sede a Henderson, Nevada.
buongiorno,
qualcuno segue questo titolo?
Ho fatto un ingresso (modesto) con 1\3 delle quote che avevo previsto.
Speravo in un rimbalzo che non c'è stato...
Attendo di capire quando entrare con la seconda quota... sembra non avere un bottom.
che ne pensate?
qualcuno segue questo titolo?
Ho fatto un ingresso (modesto) con 1\3 delle quote che avevo previsto.
Speravo in un rimbalzo che non c'è stato...
Attendo di capire quando entrare con la seconda quota... sembra non avere un bottom.
che ne pensate?
Company Profile
11500 South Eastern Avenue
Suite 240
Henderson, NV 89052
United States
702-835-6300
http://www.sppirx.comSector: Healthcare
Industry: Biotechnology
Full Time Employees: 235
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
11500 South Eastern Avenue
Suite 240
Henderson, NV 89052
United States
702-835-6300
http://www.sppirx.comSector: Healthcare
Industry: Biotechnology
Full Time Employees: 235
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
